Related Experiment Video

Updated: Jan 14, 2026

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

11.1K

Simvastatin Neuroprotective Properties against Methylphenidate-Induced Neurodegeneration: Histological and Behavioral

Mohammad Javad Shahabi1, Abbas Jafarian1, A Wallace Hayes2,3

  • 1Department of Pharmacology and Toxicology, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.

Advanced Biomedical Research
|October 24, 2025
PubMed
Abstract

Insights

Simvastatin (SIM) protects against methylphenidate (MPH)-induced behavioral and hippocampal changes in rats. This study shows SIM

Area of Science:

  • Neuroscience
  • Pharmacology
  • Histology

Background:

  • Methylphenidate (MPH) can induce behavioral and histological alterations.
  • The hippocampus is particularly vulnerable to MPH-induced neurotoxicity.

Purpose of the Study:

  • To investigate the neuroprotective effect of simvastatin (SIM) against MPH-induced neurotoxicity.
  • To evaluate SIM's impact on behavioral changes and hippocampal histology.

Main Methods:

  • Male Wistar rats were administered MPH alone or in combination with varying doses of SIM.
  • Behavioral assessments included the Open Field Test (OFT) and Elevated Plus Maze (EPM).
  • Histomorphological changes in the hippocampus (DG and CA1 regions) were analyzed.

Main Results:

  • MPH induced anxiety, depression, and motor activity disorders, along with significant hippocampal cell damage.
  • Simvastatin treatment dose-dependently ameliorated MPH-induced behavioral deficits.
  • SIM inhibited MPH-prompted quantitative and qualitative neurodegenerative changes in hippocampal DG and CA1 cells.

Conclusions:

  • Simvastatin exhibits significant neuroprotective properties against methylphenidate-induced behavioral and hippocampal damage.
  • SIM mitigates MPH-induced anxiety, depression, motor deficits, and hippocampal histopathological alterations.
Keywords:
Methylphenidateneurodegenerationneuroprotectivesimvastatin

More Related Videos

Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice09:48

Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice

Published on: May 4, 2015

14.2K
A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats10:15

A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats

Published on: November 6, 2019

8.8K

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
552
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
814
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K